Cirrhosis ursodeoxycholic acid

Multidimensional LC has also been used to determine ursodeoxycholic acid and its conjugates in serum (14). These compounds are used in the treatment of cholesterol gallstones, hepatitis and bilary cirrhosis. These authors employed a traditional (10 X 4 mm) pre-column and a micro-bore (35 X 2 mm) analytical column that were interfaced by using a six-port switching valve. [Pg.413]

L. Serfaty, A. De Leusse, O. Rosmorduc, B. Desaint, J.-F. Flejou, O. Chaouilleres, R. E. Poupon and R. Poupon, Ursodeoxycholic acid therapy and the risk of colorectal adenoma inpatients with primary biliary cirrhosis An observational study, Hepatology, 2003, 38, 203. [Pg.98]

We (K1) attempted to develop a noncompetitive assay based on the anti-idiotype antibodies for a conjugated bile acid metabolite, ursodeoxycholic acid 7-A-acetyl-glucosaminide (UDCA 7-NAG), which is expected to serve as a diagnostic index for an autoimmune disease, primary biliary cirrhosis. In our assay, the hapten UDCA 7-NAG, a /3-type antibody, and a biotin-labeled a-type antibody were simultaneously added to a microtiter plate coated with an F(ab )2 fragment of a specific anti-UDCA 7-NAG antibody, then incubated at room temperature for 8 h. Bound biotin was then detected with HRP-labeled streptavidin, whose enzyme activity was measured using o-phenylenediamine/H202 as a substrate. This noncompetitive assay system provided a subfemtomole-order sensitivity (detection limit 118 amol) that was 7 times lower than the competitive immunoassay using the same anti-hapten antibody (K2), even with a common colorimetric detection (Fig. 13). Somewhat improved specificity was also obtained namely, better... [Pg.160]

Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2001. [Pg.634]

Poupon RE, Chretien Y, Poupon R, Paumgartner G (1993) Serum bile acids in primary biliary cirrhosis effect of ursodeoxycholic acid therapy. Hepatology 17 599-604... [Pg.663]

Siegal J, Jorgensen R, Angulo P, Lindor K. Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis. J Clinical Gastroenterol 2003 37 183-5. [Pg.664]

Bateson, M.C., Gedling, P. Ursodeoxycholic acid therapy for primary biliary cirrhosis. A 10-year British single-centre population-based audit of efficacy and survival. Postgrad. Med. J. 1998 74 482-485... [Pg.667]

Battezzati, P.M., Podda, M., Bianchi, F.B., Naccarato, R., Orlandi, F., Surrenti, C, Pagliaro, L., Manenti, F. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a doubleblind multicentre trial. J. Hepatol. 1993 17 332-338... [Pg.667]

Buscher, H.-R, Zietzschmann, Y., Gerok, W. Positive response to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone. J. Hepatol. 1993 18 9-14... [Pg.668]

M. L., Miiis, S., Peters, M.G., WWte, H.M., Zetterman, R.K., Rossi, S.S., Hofmann, A.F., Markin, R.S. A randomized doubie-bhnd, pia-cebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995 22 759-766... [Pg.668]

Crosignani, A., Podda, M., Battezzati, P.M., Bertoilnl, E., Zuin, M., Watson, D., Setchell, K.D.R. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology 1991 14 1000-1007... [Pg.668]

Floreani, A., Zappala, F., Mazzetto, M., Naccarato, R., Plebani, M., Chiaramonte, M. Different response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis according to severity of disease. Dig. Dis. Sci. 1994 39 9-14... [Pg.668]

L. J., Steinbrecher, U.R, Sutherland, L.R., Williams, C.N., Witt-Sulli-van, H., Worobetz, L.J., Milner, R.A., Wanless, I.R. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994 19 1149-1156... [Pg.669]

Hwang, S.-J., Chan, C.-Y, Lee, S.-D., Wu, J.-C., Tsay, S.-H., Lo, K.-J. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis A short-term, randomized, double blind controlled, cross-over study with long-term follow up. J. Gastroenterol. Hepatol. 1993 8 217-223... [Pg.669]

Kurktschiev, D., Subat, S., Adler, D., Schenke, K.-U. Immunomodulat-ing effect of ursodeoxycholic acid therapy in patients with primary biUaiy cirrhosis. J. Hepatol. 1993 18 373-377... [Pg.669]

Baldus, W.P. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis the results of a pilot study. Hepatology 1995 22 1158-1162... [Pg.670]

Lindor, K.D., Jorgensen, R.A., Therneau, T.M., Malinchoc, M., Dickson, E.R. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin. Proc. 1997 72 1137-1140... [Pg.670]

Matsuzaki, Y., Doy, M., Tanaka, N., Shoda, J., Osuga, T., Nakano, M., Aikawa, T. Biochemical and histological changes after more than four years of treatment of ursodeoxycholic acid in primary biliary cirrhosis. J. Clin. Gastroenterol. 1994 18 36-41... [Pg.670]

Mazzella, G., Parini, P., Bazzoli, F., Villanova, N., Festi, D., Aldini, R., Roda, A., Cipolla, A., Polimeni, C., Tonelli, D., Roda, E Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis. Dig. Dis. Sci. 1993 38 896-902... [Pg.670]

R. Long-term effects of ursodeoxycholic acid in primaiy bihary cirrhosis results of a double-blind controlled multicentric trial. J. Hepatol. 2000 32 561-566... [Pg.670]

Poupon, R.E., Huet, P.M., Poupon, R., Bonnand, A.-M., Tran van Nhieu, J., Zafrani, E.S. A randomized trial comparing colchidne and ursodeoxycholic acid combination to ursodeoxycholic acid in primaiy bihary cirrhosis. Hepatology 1996 24 1098-1103... [Pg.670]

Poupon, R.E., Lindor, K.D., Pares, A., Chazouilleres, O., Poupon, R., Heathcote, E.J. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary bihary cirrhosis. J. Hepatol. 2003 39 12-16... [Pg.670]

Shibata, J., Fujiyama, S., Honda, Y., Sato, T. Combination therapy with ursodeoxycholic acid and colchicine for primary biliary cirrhosis. X Gastroenterol. Hepatol. 1992 7 277-282... [Pg.671]

Turner, I.B., Myszor, M., Mitchison, H.C., Bennet, M.K., Burt, A.D., James, O.F.W. A two-year controlled trial examining effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. J. Gastroenterol. Hepatol. 1994 4 162-168... [Pg.671]

Wolfhagen, F.H.J., van Buuren, H.R., Schalm, S.W. Combined treatment with ursodeoxycholic acid and prednisone in primary biUary cirrhosis. Neth. X Med. 1994 44 84-90... [Pg.671]

JosU, S., Canch-Dudek, K., Wanless, I.R., Lindor, K.D., Jorgensen, R., Batts, K., Heathcote, E.J. Primary biliary cirrhosis with additional features of autoimmune hepatitis response to therapy with ursodeoxycholic acid. Hepatology 2002 35 409 - 413... [Pg.675]

The above-mentioned measures do not combat the cause(s) or eliminate the primary pathogenetic reactions (with a few exceptions). The general aim is to prevent progression of the disease, ideally until the cirrhosis comes to a halt. When such medication is administered effectively, complicative developments can also be prevented. Pathogenetic primary reactions often initiate a cascade of secondary mechanisms, in particular of a biochemical nature. This is true, for example, of the inhibition of concomitant cholestasis during the course of cirrhosis by ursodeoxycholic acid (97), the reduction in lipid peroxidation by silymarin, the inhibition of fibrogenesis by colchicine (82) or silymarin (sometimes with improved quality of life), and the elimination of hyperammonaemia by ornithine aspartate. (145) (s. p. 279)... [Pg.741]

Lirussi, R, Nassuato, G., Orlando, R., lemmolo, R.M., Beccarello, A., Bortolato, L., Rustical , A.G., Okolicsanyi, L. Treatment of active cirrhosis with ursodeoxycholic acid and a free radical scavenger a two year prospective study Med. Sci. Res. 1995 23 31-33... [Pg.747]

Experience with tauroursodeoxycholic acid is limited. It is less effective than ursodeoxycholic acid and causes more adverse effects. Two patients who took tauroursodeoxycholic acid for primary biliary cirrhosis developed severe right upper quadrant pain, and rechallenge with tauroursodeoxycholic acid was positive (7). [Pg.516]

Mirave JI, Castiella A, Vargas V, Martin-Vivaldi R, Vidan JM, Zozaya JM, Planas R, Viver JM, De la Mata M, Pons F, Diaz F. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 2000 32(4) 561-6. [Pg.517]

Lee Y, Kaplan M. Treatment of primary biliary cirrhosis and primary sclerosing cholangitis Use of ursodeoxycholic acid. Curr Gastroenterol Rep 1999 1 38-41. [Pg.1836]

Papatheodoridis G, Hadziyannis E, Deutsch M, Hadziyannis S. Ursodeoxycholic acid for primary biliary cirrhosis Final results of a 12-year, prospective, randomized, controlled trial. Am J Gastroenterol 2002 97 2063-70. [Pg.1840]

AvUa MA, Berasain C, Torres L, Martfn-Duce A, Corrales FJ, Yang H, Prieto J (2000) Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol 33 907-914 Serviddio G, Pereda J, Pailardo FV, Carretero J, Borras C, Cutrin J, Vendemiale G, Poli G, Vina J, Sastre J (2004) Ursodeoxycholic acid protects against secondary biliary cirrhosis via up-regulation of y-glutamyl cysteine synthetase and prevention of mitochondrial oxidative stress. Hepatology (in press)... [Pg.104]

Dilger K, Denk A, Heeg MH, Beuers U. No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. Hepatology 2005 41 595-602. [Pg.567]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...